FDA staffers disagree on safety of one-time blockbuster diabetes drug Avandia
By APTuesday, July 13, 2010
Summary Box: Drug safety debate exposes FDA rift
DIABETES DEBATE: The Food and Drug Administration is asking a panel of outside physicians to weigh in on the safety of Avandia, a former blockbuster drug that some experts believe increases heart risks.
FDA DIVIDED: As the FDA began a two-day meeting Tuesday to discuss Avandia’s future, it became clear that the agency’s own scientists are deeply divided.
ONE STUDY, TWO VIEWS: FDA scientists gave conflicting reviews of a key study that drugmaker GlaxoSmithKline says proves its drug is safe.
YOUR VIEW POINT
